Zoetis Inc - Class A

ZTS NYSE Healthcare & Biotech Monde US98978V1035
82.20 $
4.29 %

Zoetis Inc is a global leader in the discovery, development, manufacture, and marketing of medicines and vaccines for pets and livestock.

Price history of Zoetis Inc - Class A
Price history of Zoetis Inc - Class A

Performance & Momentum

6 Months 32.19 %
1 Year 52.59 %
3 Years 51.59 %
5 Years 54.14 %

Strategic Analysis

Zoetis Inc - Class A • 2026

Zoetis is a global leader in animal health, positioned in a defensive market driven by recurring spending on pet care and livestock solutions. Its business model is built on a diversified portfolio of medicines, vaccines, and diagnostics, with a strong branded-product component and veterinary expertise that is difficult to replicate.

Strengths
  • Benchmark position in animal health with a global base of customers and veterinarians
  • Structurally resilient demand, supported by the essential nature of certain treatments
  • Broad portfolio combining medicines, vaccines, and diagnostics, which strengthens diversification
Weaknesses
  • Marked stock-market slowdown, reflecting a loss of investor confidence over the medium term
  • Sensitivity to spending trade-offs by pet owners and to livestock cycles
Momentum

Momentum appears weak and clearly deteriorated, with a distinctly bearish market trend across multiple time horizons. This weakness suggests a stock that is currently being penalized by a cautious sector re-rating or by less dynamic growth expectations, despite a fundamentally solid and defensive positioning. For investors, the case remains high quality, but the stock’s timing still looks unfavorable until the trend shows signs of stabilization.

Similar stocks to Zoetis Inc - Class A

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone